Menopause is a natural, unavoidable stage that affects thousands of Tunisian women every year. Faced with the sometimes debilitating symptoms of the climacteric, hormone replacement therapy (HRT) represents an effective treatment option. Since 2002, however, its relationship with breast cancer risk has raised legitimate questions that call for clear, informed guidance tailored to the Tunisian context.
Understanding menopause in Tunisia: specific realities
Definition and timing in the Tunisian context
Menopause, the permanent end of menstruation for at least 12 months, reflects the drop in the ovaries' production of hormones: oestrogen and progesterone. In Tunisia, the data reveal some notable particularities:
The average age of menopause stands at 51, similar to observations in the north-west of the country, while in Casablanca the average age of menopause stands at 49.8 in Morocco. The average Tunisian age of menarche, 13, is in line with regional standards.
This figure takes on particular significance when you consider that 54.4% of Tunisian patients with breast cancer are postmenopausal at the time of diagnosis.
Climacteric symptoms: their impact on Tunisian women
Menopausal symptoms affect Tunisian women in different ways. Although specific national data remain limited, regional observations point to frequent symptoms similar to those seen in Marrakech:
- Joint pain (90% of cases according to comparative Moroccan data)
- Headaches (86%)
- Fatigue (83%)
- Hot flushes and sleep disturbances
This intense set of symptoms explains why many Tunisian women seek out treatment options, despite the cultural taboos that persist around menopause in some parts of the country.
Long-term consequences: major health challenges
Bone and cardiovascular risks in Tunisia
Oestrogen deficiency accelerates bone loss after menopause, raising the risk of osteoporosis. Cardiovascular risks also increase, although the direct causal link with the hormonal decline remains debated.
These complications take on particular importance in Tunisia, where the rising female life expectancy means that a growing share of a woman's life is spent in the post-menopausal period, as in Morocco where female life expectancy reaches 71.
Hormone replacement therapy: the treatment arsenal
Compositions and methods of administration
HRT generally combines oestrogens and progestogens, except in women who have had a hysterectomy, who receive oestrogens alone. The available forms include:
- Oestrogens: patches, gels, transdermal patches or tablets
- Progestogens: mainly tablets
- Combinations: patches or tablets combining both hormones
Annual benefit-risk assessment
The modern medical approach requires an annual reassessment taking into account:
- The chosen route of administration
- The type of progestogen used
- The duration of treatment
- The time between menopause and starting treatment
- The individual's risk profile
Breast cancer: understanding the Tunisian stakes
Specific Tunisian epidemiology
Tunisian data reveal important epidemiological particularities that differ from Western standards:
In Tunisia, 54.4% of patients are postmenopausal at breast cancer diagnosis, with an average age of 51 — significantly younger than the 61 observed in the West. This earlier onset is explained in particular by the younger age pyramid of developing countries.
By comparison, in Morocco, 70.9% of patients are postmenopausal at diagnosis, with an average age of 52, illustrating significant regional variations.
Established risk factors
Several factors influence breast cancer risk:
- Age: the risk doubles every 10 years until menopause
- Genetic factors: BRCA1 and BRCA2 mutations (5–10% of cases)
- Reproductive history: early menarche, late menopause
- Parity and breastfeeding: protective factors
- Lifestyle: obesity, sedentary living
HRT and breast cancer: analysing the risks
The 2002 revelations: a historic turning point
The English-language WHI and MWS studies revealed an excess breast cancer risk linked to HRT. The International Agency for Research on Cancer (IARC) classified combined oestrogen-progestogen HRT as a definite carcinogen in 2005.
This revelation considerably reduced prescriptions, but it also deprived many women of an effective treatment for debilitating symptoms.
Nuances from the French E3N study
This large cohort study of 100,000 European women brings important nuances:
Treatments based on natural progesterone:
- No increased risk over a short period
- Increased risk beyond 5 years of use
- Lower risk than synthetic progestogens
Synthetic progestogens:
- Increased risk even over a short period
- Risk persisting up to 10 years after stopping if treatment lasted > 5 years
Oestrogens alone:
- Excess risk present but lower than with combined treatments
To help make sense of it, here is a summary of the three profiles from the E3N study:
| Type of HRT | Short-term risk | Long-term risk |
|---|---|---|
| Natural progesterone | No increased risk over a short period | Increased risk beyond 5 years of use, but lower than synthetic progestogens |
| Synthetic progestogens | Increased risk even over a short period | Risk persisting up to 10 years after stopping if treatment lasted more than 5 years |
| Oestrogens alone | Excess risk present | Lower than with combined treatments |
Quantifying the risk: a realistic perspective
The figures help put things in perspective: 8 additional cases per 10,000 women treated per year compared with those not treated. This minimal risk must be weighed against the significant improvement in quality of life.
Paradoxically, cancers detected during HRT are often smaller and have a better prognosis, probably thanks to closer medical follow-up.
Specific features of HRT in the Maghreb
Regional therapeutic differences
Maghreb practices tend to favour:
- Transdermal administration when available
- Treatments based on natural progesterone
- The lowest effective doses
- Shorter treatment durations
Cultural and socio-economic barriers in Tunisia
The under-use of HRT in Tunisia stems from several specific factors:
- Lack of awareness of the available treatment options
- Cultural taboos around menopause, still regarded as a sensitive subject
- Economic access that varies from region to region
- Still-low breast cancer screening coverage (10% according to regional data)
By way of comparison, in Morocco, only 2% of menopausal women are on treatment according to the Moroccan Association for the Study of Menopause, illustrating a shared regional challenge.
Personalised care: towards a balanced approach
Current indications for HRT
Since 2003, guidelines have restricted HRT to the following situations:
- Debilitating climacteric symptoms
- Prevention of osteoporosis in women with no alternative treatment
- Prescription at the lowest effective doses
- The shortest possible duration
A gradual withdrawal strategy
To assess whether symptoms persist, practitioners may suggest stopping for a month before the follow-up consultation. This approach makes it possible to decide calmly whether to continue or to stop for good.
Closer monitoring
Women on HRT benefit from regular mammographic follow-up, which paradoxically helps improve early breast cancer detection in this group.
Alternatives and complementary approaches
Non-hormonal options
For women reluctant to take HRT or who have contraindications:
- Specific symptomatic treatments
- Herbal medicine approaches
- Lifestyle changes
- Relaxation and stress-management techniques
Integrated prevention in Tunisia
Supporting women through menopause in Tunisia requires:
- Better information for Tunisian women
- Stronger training for the country's healthcare professionals
- The development of screening programmes accessible across the whole territory
- Consideration of specific Tunisian cultural factors
- Strengthening of the health system for better coverage
Towards personalised menopause medicine
The decision to use HRT should be the outcome of an informed dialogue between a woman and her doctor, taking into account:
- The intensity of the symptoms and their impact
- Individual risk factors
- Personal and family medical history
- The patient's preferences and concerns
- Access to alternative treatments
In the Maghreb, and particularly in Tunisia, where the demographic transition is lengthening female life expectancy, optimising post-menopausal quality of life is becoming a major public health issue. HRT, used judiciously, can contribute to this goal without significantly increasing cancer risks.
The advance of scientific knowledge now allows a more nuanced and personalised approach for Tunisian women. Every woman deserves complete, objective information so she can make informed choices about her health during this pivotal period of her life.
